Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/19/2025

LDL Targets to Halt and Reverse Atherosclerotic Plaque

Target Levels Based on Risk Category

  • The American Heart Association recommends that very high-risk patients, including those with established cardiovascular disease, achieve an LDL-C level <70 mg/dL, with at least 30-40% reduction from baseline, for halting plaque progression 1, 2, 3
  • For very high-risk patients, the optimal target for plaque regression is an LDL-C level <50 mg/dL, although the provided reference is not valid, a similar recommendation can be found for high-risk patients where an LDL-C <70 mg/dL is considered reasonable for additional cardiovascular benefit 1, 2, 6
  • The American College of Cardiology suggests that high-risk patients, including those with coronary heart disease or equivalents, should aim for an LDL-C level <100 mg/dL as a minimum target, with a reasonable target of <70 mg/dL for additional benefit 1, 2, 4, 5, 6

Evidence for Plaque Stabilization and Regression

  • The National Lipid Association states that LDL-C levels around 70-100 mg/dL slow atherosclerotic progression but may not completely halt it, with evidence from studies such as Circulation 4, 5
  • The American Heart Association indicates that there is a log-linear relationship between LDL-C and coronary heart disease risk, meaning there is no threshold below which further LDL reduction provides no benefit, with every 1.0 mmol/L reduction in LDL-C associated with a 20-25% reduction in cardiovascular events 3, 4, 5

Treatment Intensity

  • The American College of Cardiology recommends that when LDL-C is >100 mg/dL, statin therapy should be used to achieve at least 30-40% reduction, with consideration for ezetimibe or PCSK9 inhibitors if goals are not met 1, 2, 3, 6, 7
  • For patients with triglycerides ≥200 mg/dL, non-HDL-C becomes a secondary target, 30 mg/dL higher than the LDL-C goal, according to the National Lipid Association 1, 3, 7

Key Clinical Considerations

  • The European Atherosclerosis Society notes that clinical trials have demonstrated continued benefit even when reducing LDL-C from levels already <100 mg/dL, highlighting the importance of aggressive therapy in high-risk patients 4, 5
  • The American Heart Association advises against common pitfalls such as treating to 100 mg/dL and stopping, ignoring the need for aggressive therapy in patients with low baseline LDL, and focusing solely on LDL without addressing lifestyle factors 1, 3, 4, 5, 6, 7